These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7368151)

  • 1. Determination of the biological activity of heparin by use of a chromogenic substrate.
    Bartl K; Dorsch E; Lill H; Ziegenhorn J
    Thromb Haemost; 1980 Feb; 42(5):1446-51. PubMed ID: 7368151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A photometric method of determining the activity of antithrombin III using a peptide coumarylamide substrate].
    Kuznetsov VA; Pozdnev VF; Bol'shakova TD
    Lab Delo; 1990; (8):43-5. PubMed ID: 1705601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A versatile assay method of antithrombin III using thrombin and Tos-Gly-Pro-Arg-Pna.
    Bartl K; Lill H
    Thromb Res; 1980 Apr 1-15; 18(1-2):267-72. PubMed ID: 7404500
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photometric assay of antithrombin III with a chromogenic substrate.
    Vinazzer H
    Haemostasis; 1975; 4(2):101-9. PubMed ID: 1205336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
    Bombeli T; Raddatz-Mueller P; Fehr J
    Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using he substrate, H-D-Phe-Pip-Arg-p-nitroanilide-2HCl.
    Scully MF; Kakkar VV
    Clin Chim Acta; 1977 Sep; 79(3):595-602. PubMed ID: 70286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [On the determination of plasma antithrombin III with chromogenic peptide substrate (author's transl)].
    Nakamura S; Takizawa N; Nakanishi K; Igarashi M
    Rinsho Byori; 1980 Jan; 28(1):81-6. PubMed ID: 7373880
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of synthetic chromogenic substrates for the control of antithrombosis therapy with small doses of heparin].
    Bokarew IM; Butorow WN; Gordejew PS; Kusnezow WA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):142-9. PubMed ID: 6177595
    [No Abstract]   [Full Text] [Related]  

  • 16. Specific determination of plasmatic thrombin activity.
    Stief TW
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):324-9. PubMed ID: 16959686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antithrombin III assay using a chromogenic substrate in newborns].
    De Mattia D; Montagna O; Marvulli E
    Boll Soc Ital Biol Sper; 1979 Apr; 55(8):746-50. PubMed ID: 554643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238).
    Larsen ML; Abildgaard U; Teien AN; Gjesdal K
    Thromb Res; 1978 Aug; 13(2):285-8. PubMed ID: 567858
    [No Abstract]   [Full Text] [Related]  

  • 19. Automated determination of heparin with chromogenic substrates.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):184-94. PubMed ID: 6735276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times.
    Brack MJ; More RS; Hubner PJ; Gershlick AH
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):183-6. PubMed ID: 8457649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.